Trial Profile
A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2018
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Moxifloxacin; Naltrexone
- Indications Pain
- Focus Pharmacodynamics
- Sponsors Purdue Pharma
- 08 Dec 2013 New trial record